Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.23
-0.4000-6.03%
Volume:170.13K
Turnover:1.08M
Market Cap:428.18M
PE:-2.68
High:6.63
Open:6.60
Low:6.23
Close:6.63
Loading ...

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
17 Mar

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
11 Mar

JonesTrading Remains a Buy on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
08 Mar

EyePoint Pharma’s Earnings Call: Clinical Progress Amid Financial Challenges

TIPRANKS
·
07 Mar

EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
07 Mar

EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Mar

EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating

TIPRANKS
·
06 Mar

Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k

Simply Wall St.
·
06 Mar

Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
06 Mar

EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ...

GuruFocus.com
·
06 Mar

EyePoint Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
05 Mar

Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
05 Mar

EyePoint Pharmaceuticals: Q4 Earnings Snapshot

Associated Press Finance
·
05 Mar

EyePoint Pharmaceuticals' $371M Of Cash And Investments On December 31, 2024, Providing Cash Runway Into 2027 Beyond Topline Duravyu Phase 3 Wet AMD Data Expected In 2026

Benzinga
·
05 Mar

EyePoint Pharmaceuticals Q4 2024 GAAP EPS $(0.64) Misses $(0.51) Estimate, Sales $11.59M Beat $11.09M Estimate

Benzinga
·
05 Mar